Document is current
Any future updates will be listed below
-
Authors
Jarosz-Popek, Joanna
Eyileten, Ceren
Wicik, Zofia
Ahmadova, Sara
Siller-Matula, Jolanta
von Lewinski, Dirk
Sourij, Harald
Postula, Marek
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03087773 at ClinicalTrials.govDocuments that mention this clinical trial
New drugs in preclinical and early stage clinical development in the treatment of heart failure
https://doi.org/10.1080/13543784.2019.1551357
Circulating microRNA signatures differentiate type 2 diabetes and predict myocardial infarction severity: bench to bedside analysis
https://doi.org/10.1186/s40001-026-04486-7
Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial
https://doi.org/10.1186/s12933-023-01920-6
-
Funding
Funding for this research was provided by:
Warszawski Uniwersytet Medyczny (11/M/MBM/N/21)
Polish Medical Research Agency (2019/ABM/01/00037)
- License Information
-
More Information
Article History
Received: 8 September 2025
Accepted: 15 April 2026
First Online: 22 April 2026
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki (all participants provided written informed consent prior to inclusion in the study), and was approved by the relevant regulatory authorities, by the Ethics Committee of the Medical University of Graz, Austria (EK 29–179 ex 16/17; EudraCT 2016-004591-22) and registered on ClinicalTrials.gov (NCT03087773).
: Informed consent was obtained from all subjects involved in the study and written informed consent has been obtained from the patient(s) to publish this paper.
: H.S. is on the advisory board and speaker’s bureau of by Boehringer Ingelheim, NovoNordisk, Amgen, Amarin, Bayer, Eli Lilly, Cancom, and Daiichi Sankyo. D.V.L. is on the advisory board and speakers’ bureau of Abiomed, AstraZeneca, Bayer, Daiichi Sankyo, Orion, Sanofi, and Servier and receives consulting fees from Recardio Inc, Bayer, TLL, Vaxxinity Inc. Other authors report no competing interests related to this study.
